Pegloticase - Latest Advances

Safety, Tolerability, and Efficacy of Shorter Infusion Durations of Pegloticase Administered to Patients With Uncontrolled Gout Receiving Methotrexate: AGILE Trial.

Journal: Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases

Published: September 23, 2025

Updates in uricase therapy for gout.

Journal: Current opinion in rheumatology

Published: September 08, 2025

A Patient Presenting with Joint Deformities and ST-Elevation Myocardial Infarction.

Journal: Diagnostics (Basel, Switzerland)

Published: July 22, 2025

Microbial uricase enzymes in hyperuricemia management: Sources, challenges, and technological advances.

Journal: Journal of microbiological methods

Published: July 17, 2025

Infectious Complications in a Patient Receiving Immunomodulatory Therapy for Gout.

Journal: Cureus

Published: June 19, 2025

Innovative perspectives on uricase-based therapeutics for refractory gout

Journal: Zhonghua yi xue za zhi

Published: April 13, 2025

Gout Remission With Pegloticase-Induced Intensive Urate-Lowering Therapy: A Post Hoc Clinical Trial Analysis.

Journal: ACR open rheumatology

Published: April 10, 2025

Disseminated Varicella-Zoster Virus in a Patient on Pegloticase and Mycophenolate Mofetil for Gout.

Journal: Cureus

Published: April 02, 2025

Corrigendum: Quality of life improvements and clinical assessments in kidney transplant recipients undergoing pegloticase treatment for uncontrolled gout: findings of the phase 4 PROTECT clinical trial.

Journal: Frontiers in immunology

Published: March 18, 2025

Oral Urate-Lowering Therapy Use and Efficacy Following Pegloticase Treatment: Findings from a Rheumatology Network Database.

Journal: Rheumatology and therapy

Published: March 12, 2025

Filters

Safety, Tolerability, and Efficacy of Shorter Infusion Durations of Pegloticase Administered to Patients With Uncontrolled Gout Receiving Methotrexate: AGILE Trial.

Safety, Tolerability, and Efficacy of Shorter Infusion Durations of Pegloticase Administered to Patients With Uncontrolled Gout Receiving Methotrexate: AGILE Trial.

Updates in uricase therapy for gout.

Updates in uricase therapy for gout.

A Patient Presenting with Joint Deformities and ST-Elevation Myocardial Infarction.

A Patient Presenting with Joint Deformities and ST-Elevation Myocardial Infarction.

Microbial uricase enzymes in hyperuricemia management: Sources, challenges, and technological advances.

Microbial uricase enzymes in hyperuricemia management: Sources, challenges, and technological advances.

Infectious Complications in a Patient Receiving Immunomodulatory Therapy for Gout.

Infectious Complications in a Patient Receiving Immunomodulatory Therapy for Gout.

Innovative perspectives on uricase-based therapeutics for refractory gout

Innovative perspectives on uricase-based therapeutics for refractory gout

Gout Remission With Pegloticase-Induced Intensive Urate-Lowering Therapy: A Post Hoc Clinical Trial Analysis.

Gout Remission With Pegloticase-Induced Intensive Urate-Lowering Therapy: A Post Hoc Clinical Trial Analysis.

Disseminated Varicella-Zoster Virus in a Patient on Pegloticase and Mycophenolate Mofetil for Gout.

Disseminated Varicella-Zoster Virus in a Patient on Pegloticase and Mycophenolate Mofetil for Gout.

Corrigendum: Quality of life improvements and clinical assessments in kidney transplant recipients undergoing pegloticase treatment for uncontrolled gout: findings of the phase 4 PROTECT clinical trial.

Corrigendum: Quality of life improvements and clinical assessments in kidney transplant recipients undergoing pegloticase treatment for uncontrolled gout: findings of the phase 4 PROTECT clinical trial.

Oral Urate-Lowering Therapy Use and Efficacy Following Pegloticase Treatment: Findings from a Rheumatology Network Database.

Oral Urate-Lowering Therapy Use and Efficacy Following Pegloticase Treatment: Findings from a Rheumatology Network Database.

Assessment of drug induced hyperuricemia and gout risk using the FDA adverse event reporting system.

Assessment of drug induced hyperuricemia and gout risk using the FDA adverse event reporting system.

Severe Tophaceous Polyarticular Gout: A Case Report and Review of Literature.

Severe Tophaceous Polyarticular Gout: A Case Report and Review of Literature.